<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The role of parenteral and enteral/oral nutritional support in patients with cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The role of parenteral and enteral/oral nutritional support in patients with cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The role of parenteral and enteral/oral nutritional support in patients with cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aminah Jatoi, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles L Loprinzi, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul J Hesketh, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Seres, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 05, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss is common among cancer patients, and can be attributed to many causes, including mucositis, inability to ingest or absorb adequate calories because of a problem with the alimentary tract, loss of appetite, and metabolic aberrations. Unintentional weight loss may be associated with decreased quality of life (QOL) and a poorer prognosis. Furthermore, for patients who are already in a catabolic state, the increased metabolic demands associated with anticancer treatment (particularly surgery) further worsen the problem. (See
         <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">
          "Pathogenesis, clinical features, and assessment of cancer cachexia"
         </a>
         .)
        </p>
        <p>
         Intuitively, it would seem that caloric repletion, by either the enteral or parenteral route, would be the optimal approach to the treatment of cancer-associated weight loss. However, the routine use of enteral or parenteral nutritional support in patients with incurable cancer is not recommended [
         <a href="#rid1">
          1
         </a>
         ]. The routine use of nutritional support in patients with advanced incurable cancer is associated with a higher risk of treatment-related complications [
         <a href="#rid2">
          2,3
         </a>
         ], and no evidence of a survival benefit. Nevertheless, nutritional support is frequently prescribed for patients with cancer. In fact, malignant disease is the most frequent indication for home total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , accounting for approximately one-half of all cases in one large series [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         An overview of the general use of both parenteral and enteral/oral nutritional supplementation in cancer patients and detailed discussions of nutritional support related to the perioperative setting, hematopoietic cell transplantation, head and neck cancer, esophageal cancer, and in patients with advanced incurable cancers are discussed here. The use of nutritional support in surgical patients and the intensive care unit setting, and the basic principles of enteral and
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21016143">
         <span class="h1">
          NUTRITIONAL STATUS AND CANCER OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bapen.org.uk%2Fabout-bapen%2Fcommittees-and-groups%2Fmalnutrition-action-group&amp;token=uH7Ob8f5rNYmzYDKgYX6nj2YeZzpUzmfmvlGmMMgr41qL6qzmju17MMk2cqEzK9aET6GzcOPXvKU8INS3o1BJod%2FBk3lavidmC4%2FJlvxnmA%3D&amp;TOPIC_ID=2830" target="_blank">
          Malnutrition Advisory Action Group of the British Association for Parenteral and Enteral Nutrition
         </a>
         , malnutrition is defined as a deficiency in energy, protein, or other nutrients causes measurable adverse effects on tissues or body form, function, or clinical outcomes. Malnutrition occurs in 40 to 80 percent of cancer patients and is a major cause of morbidity and mortality in patients with advanced disease [
         <a href="#rid5">
          5,6
         </a>
         ]. It is particularly frequent in patients with digestive and upper aerodigestive tract tumors. Malnutrition may be related to an inability to ingest or absorb nutrients because of a problem with the alimentary tract related to the primary disease process (ie, obstructing esophageal tumor) or cancer treatment (ie, combined modality therapy for head and neck cancer, which may cause severe oral mucositis), or the cancer-associated anorexia/cachexia syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">
          "Pathogenesis, clinical features, and assessment of cancer cachexia"
         </a>
         .)
        </p>
        <p>
         Regardless of the cause, malnutrition in cancer patients is associated with poorer overall survival in various malignancies [
         <a href="#rid7">
          7-9
         </a>
         ], as well as reduced benefit from surgical [
         <a href="#rid10">
          10,11
         </a>
         ] and medical therapies [
         <a href="#rid12">
          12,13
         </a>
         ], a poorer tumor response to chemotherapy [
         <a href="#rid7">
          7,8,13
         </a>
         ], increased chemotherapy-related toxicity [
         <a href="#rid12">
          12,14,15
         </a>
         ], and poorer quality of life [
         <a href="#rid8">
          8,16-18
         </a>
         ]. It is important to point out that although several investigators refer to "malnutrition" in cancer patients, the provision of calories is often not the most appropriate response to this situation, as caloric supplementation can lead to complications and no reversal of the clinical picture. Thus, some might argue that the term "malnutrition" is a misnomer.
        </p>
        <p class="headingAnchor" id="H590424">
         <span class="h2">
          Screening for nutritional status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple scores are available for nutritional status evaluation of cancer patients. One simple to use and objective tool is the Nutritional Risk Index (NRI), which has been validated in various clinical settings, including gastrointestinal cancers [
         <a href="#rid19">
          19-21
         </a>
         ]. The NRI can be calculated as (= 1.519 x serum albumin level [g/L] + 0.417 X current weight/usual weight X 100) [
         <a href="#rid19">
          19
         </a>
         ]. Based on the NRI, patients can be classified as having no malnutrition (NRI &gt;97.5), moderate malnutrition (97.5 ≥ NRI ≥ 83.5), or severe malnutrition (NRI &lt;83.5).
        </p>
        <p>
         Additional issues related to screening for nutritional status are addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3016.html" rel="external">
          "Geriatric nutrition: Nutritional issues in older adults", section on 'Screening for nutritional status'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INDICATIONS AND BENEFITS OF NUTRITIONAL SUPPORT IN CANCER PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional support may improve outcomes in selected cancer patients. However, due to the paucity of evidence demonstrating benefit, the indiscriminate use of enteral or
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         in well-nourished or mildly malnourished patients with cancer is not recommended. Oral nutritional interventions might improve some aspects of quality of life in cancer patients who are malnourished or at risk for malnutrition, but they do not appear to improve survival. (See
         <a class="local">
          'Evidence to support benefit'
         </a>
         below.)
        </p>
        <p>
         Parenteral or enteral nutritional supplementation may be an appropriate option for cancer patients who meet
         <strong>
          both
         </strong>
         of the following criteria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are either notably malnourished or at risk of becoming so during cancer treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They have a potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment.
        </p>
        <p>
        </p>
        <p>
         There are no widely accepted guidelines for when to initiate nutritional support in cancer patients. While decisions about nutrition support are relatively easy for malnourished patients who have a potentially curable cancer but are unable to meet their nutrient needs for prolonged periods (eg, because of esophageal obstruction or intestinal failure), these decisions are more difficult when nutritional intake is closer to meeting needs, when the likely period of inadequate intake is uncertain, or in situations where the malignancy is treatable but incurable and the patient is unable to take in sufficient nutrients. In these settings, decision-making is more complex, especially given that providing nutrition support is not without risk.
        </p>
        <p class="headingAnchor" id="H2535151972">
         <span class="h2">
          Guidance from expert groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         This lack of consensus as to specific indications for nutritional support in patients with cancer is reflected in the vagueness of available guidelines from expert groups:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         International guidelines on the nutritional management of patients with cancer from the European Society for Clinical Nutrition and Metabolism (ESPEN), the American Dietetic Association, the American Society for Parenteral and Enteral Nutrition, and the Dietitians Association of Australia recommend that nutritional intervention be started in malnourished patients or those in whom difficulties with eating are anticipated [
         <a href="#rid22">
          22-25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, ESPEN has published a 2020 update on indications and contraindications for home enteral nutrition, and its implementation and monitoring [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United Kingdom, the National Institute for Health and Clinical Excellence (NICE) recommends that health care professionals consider
         <strong>
          oral
         </strong>
         nutritional support to improve nutritional intake for people who can swallow safely and who are malnourished or at risk of malnutrition (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fqs24&amp;token=lblfowwGB6QwC91WNuiIf6SDS220EiNtWYYQS8Gn6dPubY0391RqjinfAUsTkdL4&amp;TOPIC_ID=2830" target="_blank">
          NICE guidelines for nutritional support for adults
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid27">
          27
         </a>
         ] suggest consideration of nutritional support, as appropriate, in patients who have an estimated life expectancy of months to years, but not those with a life expectancy measured in weeks to months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines for managing cancer-associated cachexia from the American Society for Clinical Oncology support that it is reasonable for clinicians to refer patients with cancer and loss of appetite and/or body weight to a registered dietician for assessment and counseling with the goals of providing practical and safe advice for feeding; education regarding high-protein, high-calorie, nutrient-dense foods; and advice against fad, unproven, or other extreme diets [
         <a href="#rid1">
          1
         </a>
         ]. Outside of the context of a clinical trial, clinicians should not routinely offer enteral tube feeding or
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         to manage cachexia in advanced cancer. A short-term trial of parenteral nutrition may be offered to a very select group of patients, such as those who have reversible bowel obstruction, short-bowel syndrome, or other issues contributing to malabsorption, but otherwise are reasonably fit. Discontinuation of previously initiated enteral or parenteral nutrition near the end of life is appropriate. (See
         <a class="local">
          'Patients with cancer at the end of life'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 2020, the European Society of Medical Oncology endorsed comfort-directed care as the primary nutritional goal for patients with only a few estimated (three to six) weeks of life, less invasive nutritional interventions for patients with less than three to six months of estimated life, and that regular screening and nutritional interventions should be considered in patients with more than three to six months of estimated life expectancy [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Multinational Association of Supportive Care in Cancer (MASCC) has developed evidence-based recommendations for clinically assisted nutrition in patients with cancer, but they do not address specific indications for nutritional support beyond a recommendation not to pursue any form of clinically assisted nutrition for treatment of cancer cachexia [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2907713551">
         <span class="h2">
          Evidence to support benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evidence to support benefit from either parenteral or enteral nutritional intervention in patients with cancer is limited:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review of the literature by the American Gastroenterological Association (AGA) identified 26 randomized trials of parenteral nutritional support in cancer patients, including 19 in those receiving chemotherapy, three in patients being treated with radiation therapy (RT), and four in those undergoing stem cell transplantation [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Key observations included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 19 trials with 1050 patients, the use of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         did not significantly decrease mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In eight trials that included 333 patients where information was available regarding overall complications, there was a statistically significant 40 percent increase in the total complication rate in the treated group. The incidence of infectious complications was significantly increased, by 16 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 15 assessable trials that included 910 patients where tumor response data were provided, the tumor response rate was significantly lower (by an absolute value of 7 percent) in patients receiving
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least four systematic reviews have addressed the role of enteral/oral nutritional support in cancer patients; none demonstrates a survival benefit [
         <a href="#rid2">
          2,30-32
         </a>
         ]. The most recent and largest of these included 13 randomized trials of oral nutritional intervention (dietary advice, oral nutritional supplements, or both) totaling 1414 participants with a variety of cancer types [
         <a href="#rid30">
          30
         </a>
         ]. Trials were included if they were undertaken in adults who were clearly malnourished (although the definitions of malnourished differed according to trial) or were judged to be at risk for malnutrition on the basis of their clinical condition, and were receiving active anticancer treatment or palliative care; the included trials compared oral nutritional intervention with usual care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Key observations included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All trials were judged to be of low to moderate quality and at risk for bias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There was considerable clinical (cancer site and stage, length and type of dietetic intervention, baseline nutritional status) and statistical heterogeneity among the trials. Only four defined baseline nutritional status as an inclusion criterion; six included both well-nourished and malnourished patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nutritional intervention was associated with statistically significant improvements in weight (mean difference 1.8 kg) and energy intake (mean difference 432 kcal) compared with routine care; however, these differences were no longer apparent when the data from trials that contributed the most to statistical heterogeneity were removed from the analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nutritional intervention provided significant benefit for some aspects of quality of life (emotional functioning, dyspnea, loss of appetite, global quality of life) but had no impact on mortality (relative risk for death in the intervention group 1.06, 95% CI 0.92-1.22).
        </p>
        <p>
        </p>
        <p>
         These data suggest that oral nutritional interventions might improve some aspects of quality of life in cancer patients who are malnourished or at risk for malnutrition, but they do not appear to improve cancer outcomes.
        </p>
        <p>
         The best patients for consideration of nutritional intervention have a potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment. The following sections will describe the use of and evidence for the benefit of nutritional support in specific clinical scenarios.
        </p>
        <p class="headingAnchor" id="H1289635387">
         <span class="h2">
          Specific clinical scenarios in which nutritional support may be considered
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          The perioperative setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative malnutrition is associated with poor postoperative outcomes in patients undergoing surgery for cancer [
         <a href="#rid33">
          33-36
         </a>
         ]. Although multiple studies have failed to demonstrate a survival benefit from perioperative nutrition support in patients undergoing major cancer surgery [
         <a href="#rid37">
          37-40
         </a>
         ], others have documented fewer operative complications and a shorter length of hospital stay in malnourished patients who receive nutritional support [
         <a href="#rid19">
          19,41-43
         </a>
         ]. In general:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients undergoing major surgery for cancer who have severe malnutrition may derive benefit from nutritional support and, if feasible and safe, delaying surgery to be fed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients clearly benefit more from enteral feeding, whenever possible, rather than total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         (TPN), as TPN is associated with an increased risk for infectious complications. However, TPN may be justified in a malnourished patient undergoing cancer surgery when enteral nutrition is not a viable option and where there is a strong possibility that a patient may be cured of his or her malignancy or attain a substantial improvement in survival as a result of cancer therapy. Even under these circumstances, the benefits of parenteral nutrition must be counterbalanced by the risks associated with its use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The role for immunonutrition (ie, enteral formulas that are supplemented with L-arginine, RNA nucleotides, and omega-3 fatty acids) is unclear. Thus far, there is insufficient high-quality evidence to suggest any specific amino acid or other supplementation for surgical patients with cancer. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients who undergo allogeneic hematopoietic cell transplantation (HCT) develop significant mucositis and have difficulty maintaining adequate caloric intake. The degree of mucositis is related to the particular cytotoxic regimen. Oral intake may be further compromised by the development of acute graft-versus-host disease (GVHD) affecting the alimentary tract. Parenteral nutritional support is commonly administered prophylactically to such patients until they are able to maintain adequate oral nutritional intake, which usually does not occur until the bone marrow recovers. (See
         <a class="medical medical_review" href="/z/d/html/1152.html" rel="external">
          "Oral toxicity associated with systemic anticancer therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h4">
          Total parenteral nutrition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial support for the routine use of TPN during HCT was provided by an older study that randomly assigned 137 previously well-nourished patients undergoing HCT for a variety of different malignancies (predominantly acute leukemia) to either prophylactic TPN or intravenous maintenance fluids (5 percent dextrose, electrolytes, minerals, trace elements, and vitamins) [
         <a href="#rid44">
          44
         </a>
         ]. Treatment was initiated during cytoreductive chemotherapy, and continued for four weeks following transplantation. Compared with controls, patients receiving TPN had significantly better overall and disease-free survival, and a longer time to relapse. This difference occurred despite the fact that 61 percent of control patients eventually started TPN because of a decline in nutritional status.
        </p>
        <p>
         In part because this study was performed a number of years ago, many questions regarding nutritional support in the setting of HCT remain unanswered. The care of patients undergoing HCT has undergone marked change over the last 20 years. Hospital stays are shorter, and with other improvements in supportive care (eg, better antiemetics, use of recombinant hematopoietic growth factors, better prophylaxis against GVHD), and the increasing use of autologous transplantation, the appropriate use of TPN in transplant patients is deserving of future trials.
        </p>
        <p>
         These additional studies have not provided firm support for the routine use of TPN in patients undergoing HCT:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one trial, 57 patients undergoing HCT were randomly assigned to prophylactic TPN or to an enteral feeding program [
         <a href="#rid45">
          45
         </a>
         ]. TPN was associated with significantly more days of diuretic use, more frequent hyperglycemic episodes, and more catheter-related complications. This study was smaller than the trial referenced above, but nonetheless suggests that the role of TPN in patients undergoing HCT deserves further investigation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second trial, 258 patients who were discharged following marrow infusion were randomly assigned to either TPN or intravenous hydration [
         <a href="#rid46">
          46
         </a>
         ]. TPN did not influence the rate of hospital readmission, relapse rate or overall survival [
         <a href="#rid46">
          46
         </a>
         ]. In fact, patients undergoing TPN had a longer median time to resume &gt;85 percent of their caloric requirement (16 versus 10 days), suggesting that the administration of TPN suppressed the return of normal appetite. Furthermore, nutrition-related costs were 2.3-fold greater in the TPN group. Although this study did not examine the issue of whether prophylactic TPN is indicated in patients who receive HCT, it does suggest that after hospital discharge, TPN does not appear to be necessary in all patients.
        </p>
        <p>
        </p>
        <p>
         One study attempted to define specific subgroups of patients who had hematologic malignancies, who were undergoing intensive cytotoxic chemotherapy with or without HCT, and who were likely to require TPN [
         <a href="#rid47">
          47
         </a>
         ]. The following criteria were used to define the need for TPN:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe malnutrition at admission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prolonged period (7 to 10 days) of minimal oral intake
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical weight loss during treatment exceeding 10 percent of body weight
        </p>
        <p>
        </p>
        <p>
         Using these definitions, TPN was judged to be necessary in only 55 percent of patients undergoing HCT, ranging from 37 percent of autologous recipients, to 92 percent of those receiving an HLA mismatched allograft (the latter being associated with a higher rate of GVHD). (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Further studies will be required to determine whether TPN should be used based on need, or prophylactically in all patients regardless of nutritional status. Until then, it seems prudent to administer TPN to patients who are undergoing HCT and who have severe mucositis or gastrointestinal manifestations of GVHD, when a long period of insufficient oral intake is anticipated.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h4">
          Glutamine supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          Glutamine
         </a>
         is an important precursor for nucleotide synthesis, and an important fuel source for rapidly dividing cells, such as the lining epithelia of the GI tract. Furthermore, glutamine is postulated to facilitate healing of the GI mucosa following damage by either radiation therapy (RT) or chemotherapy [
         <a href="#rid48">
          48
         </a>
         ]. Although considered a nonessential amino acid, glutamine is a conditionally essential amino acid during periods of stress [
         <a href="#rid49">
          49
         </a>
         ]. It is not usually included in TPN formulations due to stability issues.
        </p>
        <p>
         Animals sustained on TPN develop atrophy of the gut, an effect that may be ameliorated by
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation [
         <a href="#rid50">
          50,51
         </a>
         ]. These data have led to the study of glutamine supplementation, both parenterally and enterally, in patients undergoing hematopoietic cell transplantation.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h5">
          Parenteral supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         It cannot be definitively concluded based on the limited available data that there is benefit for parenteral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation in patients undergoing HCT.
        </p>
        <p>
         Two small trials have evaluated the role of parenteral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation in patients undergoing HCT [
         <a href="#rid52">
          52,53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, 45 patients undergoing allogeneic HCT for hematologic malignancies were randomly assigned to parenteral TPN with
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation (0.57 g/kg per day) or an isocaloric, isonitrogenous glutamine-free TPN formula [
         <a href="#rid52">
          52
         </a>
         ]. The glutamine-supplemented group had significantly lower infection (13 versus 43 percent) and colonization rates, better nitrogen balance, a decreased incidence of infection, and a shorter length of stay (29 versus 36 days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second report, 29 patients with both hematologic and solid malignancies undergoing either allogeneic or autologous HCT were randomly assigned to supplemental parenteral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         or placebo [
         <a href="#rid53">
          53
         </a>
         ]. Despite finding a similar six day shorter length of hospital stay in the glutamine group, there were no significant differences in the incidence of positive bacterial cultures, clinical infections, or mortality.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h5">
          Enteral supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least two trials of oral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation have failed to confirm any benefit in patients undergoing HCT:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the first, 193 patients undergoing autologous or allogeneic HCT were randomly assigned to oral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         (1 gm/m
         <sup>
          2
         </sup>
         four times daily) or supplemental glycine (placebo) from days 1 through 28 [
         <a href="#rid54">
          54
         </a>
         ]. The glutamine-supplemented group undergoing autologous HCT had significantly less mouth pain and opiate use than controls, but no difference was seen in the allogeneic patients. The authors postulated an interaction with the individual chemotherapy regimens to explain this difference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a similarly designed second study, 66 patients with either hematologic or solid tumors undergoing allogeneic or autologous HCT were randomly assigned to oral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         (30 gm per day) or a glycine placebo [
         <a href="#rid55">
          55
         </a>
         ]. There were no significant differences between the groups in length of hospital stay, number of TPN days, neutrophil recovery time, incidence of positive blood cultures, sepsis, mucositis, or diarrhea. There was only a suggestion of improved long-term survival with glutamine, and a possible reduction in the need for TPN.
        </p>
        <p>
        </p>
        <p>
         Thus, the impact of oral
         <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">
          glutamine
         </a>
         supplementation to prevent gut atrophy and decrease mucositis and infectious complications in patients undergoing HCT remains controversial.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Head and neck cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Head and neck cancer (HNC) is commonly diagnosed at an advanced stage. In addition to the alterations in chewing and swallowing that can accompany specific tumors or their surgical treatment, aggressive chemotherapy and RT can lead to dysphagia, odynophagia, and dehydration, all of which may result in malnutrition, treatment interruption, and morbidity [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3369.html" rel="external">
          "Health-related quality of life in head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3380.html" rel="external">
          "Overview of treatment for head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h4">
          Nutritional support during RT and combined modality therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with HNC undergo radiation therapy (RT) rather than surgery for local control. Concurrent or sequential chemotherapy and RT represents a promising approach for patients with advanced HNC, particularly for preservation of organ function. However, combined therapy is associated with enhanced mucosal toxicity; loss of 8 to 10 percent of body weight is common, even with early nutritional support [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">
          "Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"
         </a>
         .)
        </p>
        <p>
         Research has focused primarily on three areas: nutritional support versus no support, prophylactic versus "as needed" support, and the optimal way to deliver enteral nutrition (gastrostomy versus nasogastric tube [NGT] feeding).
        </p>
        <p class="headingAnchor" id="H1613474900">
         <span class="h5">
          Support versus no support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retrospective series suggest that patients with HNC who receive nutritional support have less weight loss and fewer hospitalizations for treatment-related complications. As an example, in an observational series of 88 patients with locally advanced HNC treated with accelerated twice-daily RT (n = 59) or concurrent chemoradiotherapy (n = 29), 36 had undergone gastrostomy tube placement prior to starting therapy [
         <a href="#rid59">
          59
         </a>
         ]. Enterally supplemented patients had significantly less average weight loss during therapy (3.1 versus 7.0 kg), required significantly fewer hospitalizations for dehydration and malnutrition, and had fewer interruptions in their cancer treatment (0 versus 18 percent). (See
         <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">
          "Management and prevention of complications during initial treatment of head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2568.html" rel="external">
          "Gastrostomy tubes: Uses, patient selection, and efficacy in adults"
         </a>
         .)
        </p>
        <p>
         On the other hand, whether the benefits of enteral nutritional support translate into better outcomes from cancer therapy is unclear. In a randomized trial, 40 patients with inoperable squamous cell carcinoma of the nasopharynx and oropharynx were randomly assigned to oral nutrition or intensive nasogastric tube feedings during RT [
         <a href="#rid60">
          60
         </a>
         ]. Despite the significantly higher caloric intake of the NG-supplemented group, and less weight loss during treatment in this group, radiation response rates and overall survival were similar. Slightly more patients who received tube feedings returned to their regular activities after six months of follow-up, compared with controls (62 versus 45 percent). This trial had limited power to find significant differences with its small sample size.
        </p>
        <p class="headingAnchor" id="H2000847984">
         <span class="h5">
          Prophylactic versus as needed support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the comparative evidence is not robust, retrospective and prospective studies comparing prophylactic with "as needed" feeding tube placement in patients receiving chemoradiotherapy for HNC have come to the following conclusions [
         <a href="#rid61">
          61
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One trial showed a modest improvement in malnutrition with prophylactic therapy [
         <a href="#rid62">
          62
         </a>
         ], but among lower quality studies, there were no differences in body mass index (BMI) at six months posttreatment or in the amount of weight loss during treatment [
         <a href="#rid63">
          63-69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Only one [
         <a href="#rid64">
          64
         </a>
         ] of five studies [
         <a href="#rid63">
          63-67
         </a>
         ] found that prophylactic feeding tubes prevented unplanned treatment interruptions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No study reported better disease-free survival with prophylactic nutritional support [
         <a href="#rid62">
          62,65-69
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Feeding tubes can adversely affect quality of life (QOL) by interfering with family life, intimacy, and social activities [
         <a href="#rid70">
          70
         </a>
         ]. However, two prospective randomized trials found that, after an initial decline, HNC patients who were receiving chemoradiotherapy and were randomized to receive feeding tubes had improved QOL at six months post completion of treatment [
         <a href="#rid62">
          62,66
         </a>
         ]. Given the limited available data, the end decision regarding the preventative use of feeding tubes needs to be made on a case-by-case basis, taking into account the clinical status of each individual patient and their values, concerns, and preferences.
        </p>
        <p class="headingAnchor" id="H761034816">
         <span class="h5">
          Gastrostomy versus nasogastric tube versus oral support
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal method of nutritional support for HNC is not established. In the absence of well-conducted, robust clinical data, it is impossible to provide definitive conclusions on whether gastrostomy feedings or NGT feedings are preferable. In our own anecdotal experience, however, the NGT seems less preferable to gastrostomy placement in the eyes of health care providers because of discomfort, negative cosmetic effects, fears of erosion of the tubing into surrounding structures as it sits in the nostril and descends beyond the oropharynx, less secure positioning, and even hypothetical concerns for tumor seeding with initial insertion. However, decisions need to be undertaken on a case-by-case basis with input from the patient and other members of the health care team.
        </p>
        <p>
         In uncontrolled studies of patients undergoing combined modality therapy for HNC, prophylactic nutritional support has been associated with increase in body weight, preservation of pretreatment nutritional status, improved QOL, fewer toxicity-related treatment interruptions, and shorter duration of hospitalization [
         <a href="#rid71">
          71-75
         </a>
         ]. However, as with RT alone, it is unclear whether the enteral nutritional support improves overall outcomes from therapy, especially survival; prospective investigations have not been conducted.
        </p>
        <p>
         There is insufficient evidence to determine the optimal method of enteral feeding in HNC patients who are receiving multimodality therapy [
         <a href="#rid76">
          76
         </a>
         ]. A single randomized trial comparing gastrostomy with NGT approaches in patients undergoing chemoradiotherapy for HNC (which closed early for slow accrual with only 33 patients eligible for analysis) concluded that there were no significant differences in complication rates or patient assessment of QOL; gastrostomy feedings were 10 times more costly than NGT feedings, and the duration of gastrostomy tube use was significantly longer (139 versus 66 days) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Additional data are available from two retrospective comparative studies. In one, gastrostomy feeding was associated with better cosmesis, mobility and QOL [
         <a href="#rid72">
          72
         </a>
         ], while the other suggests that nutritional support delivered through a gastrostomy was associated with a longer duration of support (28 versus 8 weeks) and more dysphagia after completion of treatment [
         <a href="#rid73">
          73
         </a>
         ]. Approximately 8 to 20 percent of long-term survivors become gastrostomy tube-dependent. Preexisting swallowing difficulties and advanced T-stage were associated with an increased risk of prolonged gastrostomy tube dependence.
        </p>
        <p>
         Long-term QOL may be affected by the prolonged presence of gastrostomy tubes following primary surgery for oral and oropharyngeal cancers [
         <a href="#rid78">
          78
         </a>
         ]. Follow-up of 243 patients who had surgery for oropharyngeal cancer noted that those patients with gastrostomy tubes still in place (median 34 months) had a poorer QOL than patients who had their gastrostomy tubes removed (median seven months) [
         <a href="#rid70">
          70
         </a>
         ]. The major gastrostomy tube-related problems were not leakage, blockage, or discomfort, but interference with family life, intimate relationships, social activities, and hobbies. It should be noted that these data do not prove that poorer QOL in long-term gastrostomy tube patients is necessarily due to the gastrostomy tubes that are present, which could be influenced by the fact that patients with more severe disease (cancer and/or complications of cancer treatment) need to have the gastrostomy tubes in place for a longer time.
        </p>
        <p>
         For patients who are able to swallow, aggressive oral nutritional support may provide similar benefit to gastrostomy feedings, as illustrated by the following two trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one small trial, patients undergoing RT for HNC were randomly assigned to aggressive oral feeding with nutritional supplements or no additional nutritional support [
         <a href="#rid79">
          79
         </a>
         ]. Treatment-related toxicity necessitated interruption of RT in significantly more patients not receiving nutritional support (5 of 12 compared with 0 of 11). However, radiation outcomes were not reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A benefit for dietary counseling was suggested in a trial in which 75 patients with HNC undergoing RT were randomly assigned to dietary counseling with regular foods (n = 25), usual diet plus supplements (n = 25), or usual diet only [
         <a href="#rid80">
          80
         </a>
         ]. At three months, patients who received dietary counseling improved their oral intake, while those in the other two groups returned to, or below, baseline. The dietary counseling group also had the greatest improvement in anorexia, xerostomia, and dysgeusia at three months. QOL outcomes also favored dietary counseling.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1782144178">
         <span class="h5">
          Immunonutrition versus standard nutrition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunonutrition refers to enteral formulas that are supplemented with L-arginine, RNA nucleotides, and omega-3 fatty acids. Benefit of immune-enhanced nutritional support in the perioperative setting is unclear and is addressed elsewhere and below. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support", section on 'Immune-enhancing nutritional supplements'
         </a>
         and
         <a class="local">
          'Perioperative nutritional support'
         </a>
         below.)
        </p>
        <p>
         The benefit of immunonutrition versus standard nutrition for patients undergoing chemoradiotherapy was addressed in a systematic review and meta-analysis; of the 27 included trials, six were conducted entirely in head and neck cancer [
         <a href="#rid81">
          81
         </a>
         ]. The trials were generally small (ranging from 17 to 70 patients). Among this subgroup, the risk of oral mucositis was not significantly improved by the use of immunonutrition (risk ratio 0.97, 95% CI 0.92-1.02).
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h4">
          Perioperative nutritional support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malnourished patients who are undergoing resection for HNC may benefit from perioperative nutritional support. In one report, factors associated with the need for long-term nutritional support included heavy alcohol use, tongue base surgery or pharyngectomy, myocutaneous flap reconstruction, or the need for postoperative RT [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         The benefit of immunonutrition in this setting is controversial as indicated by the following data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one double-blind trial, 136 patients undergoing resection for HNC were randomly assigned to perioperative nutritional supplementation with
         <a class="drug drug_general" data-topicid="8883" href="/z/d/drug information/8883.html" rel="external">
          arginine
         </a>
         , omega-3 fatty acids and RNA, or a standard enteral nutritional formula [
         <a href="#rid83">
          83
         </a>
         ]. Patients receiving the supplemented formula had significantly fewer postoperative infectious complications and a higher serum albumin concentration when compared with standard formula.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contrasting results were noted in a second small trial of 49 patients who had HNC and a preoperative weight loss &gt;10 percent of body weight and who were randomly assigned to standard postoperative tube feeding, preoperative plus postoperative tube feeding, or arginine-supplemented preoperative and postoperative tube feeding [
         <a href="#rid84">
          84
         </a>
         ]. Compared with only postoperative feeding, preoperative enteral nutrition with or without
         <a class="drug drug_general" data-topicid="8883" href="/z/d/drug information/8883.html" rel="external">
          arginine
         </a>
         supplementation did not significantly improve nutritional status, decrease the incidence of major postoperative complications, or alter survival.
        </p>
        <p>
        </p>
        <p>
         Perioperative immunonutrition is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support", section on 'Immune-enhancing nutritional supplements'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Esophageal cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional issues are important for patients with localized esophageal cancer. Many of these patients present in a nutritionally depleted state from progressive dysphagia. Some degree of malnutrition is present in up to 80 percent of patients at presentation [
         <a href="#rid85">
          85,86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Patients who undergo multimodality therapy for esophageal or esophagogastric junction (EGJ) cancer often have significantly worse nutritional parameters than do those who only undergo resection [
         <a href="#rid87">
          87
         </a>
         ]. The side effects of chemotherapy include nausea, vomiting, and diarrhea; the use of concurrent radiation therapy frequently causes odynophagia that further aggravates preexisting dysphagia [
         <a href="#rid88">
          88,89
         </a>
         ]. Malnutrition itself reduces the rate of patient tolerance of a complete chemoradiotherapy regimen [
         <a href="#rid90">
          90
         </a>
         ], and it becomes an even more important issue among patients who are candidates for esophagectomy following chemoradiotherapy [
         <a href="#rid87">
          87,91,92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas"
         </a>
         .)
        </p>
        <p>
         Many patients who are able to eat upon initial presentation will require some form of supplementation during the course of therapy [
         <a href="#rid90">
          90,93
         </a>
         ]. Because of this, some centers advocate routine placement of a feeding tube in all patients undergoing multimodality treatment [
         <a href="#rid94">
          94,95
         </a>
         ], although this is not a universal practice.
        </p>
        <p>
         Early evaluation and intervention by a dietitian can identify patients who have nutritional risk factors [
         <a href="#rid96">
          96
         </a>
         ], and who may benefit from close nutritional monitoring and potentially from nutritional interventions [
         <a href="#rid95">
          95,97
         </a>
         ]. Dietary measures alone (oral nutritional supplements, frequent small meals during treatment with avoidance of abrasive, spicy, or acidic foods) may allow some patients to maintain nutrition through the course of therapy [
         <a href="#rid85">
          85
         </a>
         ]. While the use of oral nutritional supplementation does not dramatically alter surgical outcomes [
         <a href="#rid98">
          98-101
         </a>
         ], it improves perioperative weight gain [
         <a href="#rid102">
          102,103
         </a>
         ].
        </p>
        <p>
         Patients who fail conservative measures may need additional nutritional supplementation. While the evidence base to support the benefit of supplemental feeding is weak, retrospective series suggest that nutritional support may improve the higher mortality associated with preoperative nutritional depletion in patients undergoing neoadjuvant chemoradiotherapy, and prevent further nutritional deterioration [
         <a href="#rid104">
          104-106
         </a>
         ]. In a retrospective review of 30 patients who were unable to maintain an oral diet and who received total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         (TPN) during neoadjuvant therapy for esophageal cancer, the patients receiving TPN tolerated higher doses of chemotherapy than did those who did not, and their surgical outcomes were similar to that of patients who were able to maintain an oral diet [
         <a href="#rid99">
          99
         </a>
         ]. Whether the benefit had anything to do with TPN, or was simply a reflection of patient selection bias is unclear.
        </p>
        <p>
         Although randomized trials have failed to demonstrate either improved treatment tolerance, or a survival benefit from nutritional support, they were not restricted to malnourished patients [
         <a href="#rid98">
          98-101
         </a>
         ]. Benefit has been shown when this intervention is restricted to malnourished patients undergoing major cancer surgery. (See
         <a class="local">
          'The perioperative setting'
         </a>
         above.)
        </p>
        <p>
         Timing of the nutritional support may also be a relevant factor. Many studies have provided only postoperative nutritional support. Others have noted a trend toward a decrease in major postoperative complications in esophageal cancer patients who were malnourished and who received TPN prior to surgery when compared with those who did not receive TPN or received it only after surgery [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6369471">
         <span class="h4">
          Special issues related to enteral feeding support
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who need adjunctive nutritional support, enteral nutritional support is generally seen as superior to
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         in a patient with a functioning gut. In the postoperative setting, it is associated with fewer complications and more efficacious reversal of malnutrition. (See
         <a class="local">
          'The perioperative setting'
         </a>
         above.)
        </p>
        <p>
         There are some special considerations for enteral feeding support in patients who are being treated for esophageal cancer:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most of the experience with tube feeding in cancer patients comes from the use of gastrostomy tubes. However, gastrostomy tubes are sometimes avoided in operable patients with esophagus cancer because of the risk of injuring the gastroepiploic artery, thus rendering the stomach unusable as a replacement conduit for the esophagus. However, others have shown that gastrostomy placement is safe in the setting of esophageal cancer, and that it does not compromise the stomach or esophagogastric anastomosis [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gastrostomy tube placement using a pull-through technique may risk tumor seeding from the tumor site to the gastrostomy tract by mechanical transfer [
         <a href="#rid108">
          108
         </a>
         ]. Although the magnitude of this risk and the clinical consequences are not entirely clear, alternative means of gastrostomy tube placement (eg, direct insertion) may be better for such patients. (See
         <a class="medical medical_review" href="/z/d/html/2552.html" rel="external">
          "Gastrostomy tubes: Complications and their management", section on 'PEG tract tumor seeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placement of a jejunostomy (J) tube avoids potential injury to the stomach. J tubes can be placed using either an open or a laparoscopic technique. J tubes can also be placed via a percutaneous endoscopic technique, but compared with gastrostomy tubes, rates of moderate to severe complications are higher (2 to 10 percent), and success rates are lower (approximately 70 percent). (See
         <a class="medical medical_review" href="/z/d/html/2583.html" rel="external">
          "Enteral feeding: Gastric versus post-pyloric"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21016357">
         <span class="h2">
          Patients with cancer at the end of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with advanced cancer who are terminally ill and who have an estimated life span that is measured in weeks to a few months, we suggest against the use of enteral or total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         support.
        </p>
        <p>
         The great majority of patients in the terminal phase of an advanced illness, such as cancer, reduce their oral intake before death, either voluntarily or because they are unable to take in sufficient nutrients and fluids for a variety of reasons, such as appetite loss, nausea, vomiting, dysphagia, generalized weakness, gastrointestinal tract obstruction, or impaired cognition. While nutrient supplementation might appear ideal to control or reverse malnutrition, the routine use of nutritional support in patients with advanced incurable cancer is associated with a higher risk of treatment-related complications, and no evidence of a survival benefit, although the quality of the evidence is low [
         <a href="#rid2">
          2,3,109-113
         </a>
         ]. Several groups such as the Working Group for Developing Guidelines for
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          Parenteral Nutrition
         </a>
         of the German Association for Nutritional Medicine, the NCCN [
         <a href="#rid27">
          27
         </a>
         ], and the American Society of Parenteral Nutrition (ASPEN), specifically recommend against routine administration of parenteral nutrition in patients with advanced cancer [
         <a href="#rid22">
          22,114,115
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14244.html" rel="external">
          "Stopping nutrition and hydration at the end of life", section on 'Use of artificial nutrition'
         </a>
         .)
        </p>
        <p>
         However, in highly selected patients (eg, high-grade bowel obstruction or malabsorption from advanced cancer) who might otherwise have a prognosis that is measured in several months or years, home parenteral nutritional support may be considered after extensive deliberation among the health care staff, the patient, and caregivers [
         <a href="#rid116">
          116,117
         </a>
         ]. Even under such circumstances, however, the use of
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         is the exception rather than the rule. Central venous access device selection, which is based in part on anticipated duration of use, is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">
          "Central venous access: Device and site selection in adults", section on 'Factors influencing catheter selection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1597516987">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111340.html" rel="external">
          "Society guideline links: Nutrition support (parenteral and enteral nutrition) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15097543">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16248.html" rel="external">
          "Patient education: Managing loss of appetite and weight loss with cancer (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/141278.html" rel="external">
          "Patient education: Malnutrition (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/141279.html" rel="external">
          "Patient education: Malnutrition – Discharge instructions (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutritional status and cancer outcomes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malnutrition occurs in 40 to 80 percent of cancer patients (especially upper aerodigestive tract tumors) and is a major cause of morbidity and mortality in those with advanced disease. Malnutrition is associated with poorer overall survival, reduced benefit from cancer therapy, increased chemotherapy-related toxicity, and poorer quality of life. (See
         <a class="local">
          'Nutritional status and cancer outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In some cases, malnutrition may be related to an inability to ingest or absorb nutrients because of the primary disease process or its treatment, but in most cases, it is attributable to cancer-associated anorexia/cachexia syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">
          "Pathogenesis, clinical features, and assessment of cancer cachexia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Use of the term "malnutrition" does not indicate that the provision of nutrition is the answer to this set of circumstances.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple scores are available for assessing nutritional status of cancer patients. One simple to use and objective tool is the Nutritional Risk Index. (See
         <a class="local">
          'Screening for nutritional status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and benefits of nutritional support
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nutritional support may improve outcomes in selected cancer patients. However, due to the paucity of evidence demonstrating benefit, the indiscriminate use of enteral or
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         in well-nourished or mildly malnourished patients with cancer is not recommended. (See
         <a class="local">
          'Indications and benefits of nutritional support in cancer patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oral nutritional interventions might improve some aspects of quality of life in cancer patients who are malnourished or at risk for malnutrition, but they do not appear to improve survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Parenteral or enteral nutritional supplementation may be an appropriate option for cancer patients who meet
         <strong>
          both
         </strong>
         of the following criteria:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         They are either notably malnourished or at risk of becoming so during cancer treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         They have a potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among patients with advanced incurable cancers, total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         appears to be justified only if the patient has trouble with oral or enteral nutrition because of intestinal failure (eg, short bowel syndrome or unresectable obstruction) and if they otherwise have a prognosis that would likely be measured in terms of many months or years. Even under these circumstances, the benefits of parenteral nutrition must be counterbalanced by the risks associated with its use. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific clinical scenarios in which nutritional support may be considered
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Given the results of available randomized trials, we recommend that adjunctive nutritional therapy for cancer patients be limited to the following circumstances (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Malnourished patients who are undergoing major abdominal surgery. (See
         <a class="local">
          'The perioperative setting'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         During hematopoietic cell transplantation for patients who have severe mucositis or gastrointestinal manifestations of graft-versus-host disease, when a long period of insufficient oral intake is anticipated. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         During combined modality therapy for head and neck cancer. (See
         <a class="local">
          'Head and neck cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A role of nutritional support in patients with localized esophageal cancer who are undergoing concurrent chemotherapy and radiation therapy followed by surgery is less clear. Although some centers advocate routine placement of a feeding tube in all patients undergoing multimodality treatment, this is not a universal practice. The use of nutritional support in these patients should be decided on a case-by-case basis. (See
         <a class="local">
          'Esophageal cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with cancer at the end of life
         </strong>
         – For most patients with advanced cancer who are terminally ill and who have an estimated life span that is measured in weeks to a few months, we suggest against the use of enteral or total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         support (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients with cancer at the end of life'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Roeland EJ, Bohlke K, Baracos VE, et al. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol 2020; 38:2438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 2006; 130:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000; 34:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 1999; 8:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senesse P, Assenat E, Schneider S, et al. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev 2008; 34:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagoe RT, Goodship TH, Gibson GJ. The influence of nutritional status on complications after operations for lung cancer. Ann Thorac Surg 2001; 71:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rey-Ferro M, Castaño R, Orozco O, et al. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 1997; 13:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barret M, Malka D, Aparicio T, et al. Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology 2011; 81:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas S, Deville JL, Giorgi R, et al. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma. Radiother Oncol 2008; 87:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslani A, Smith RC, Allen BJ, et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Eys J. Effect of nutritional status on responses to therapy. Cancer Res 1982; 42:747s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerlid E, Wirblad B, Sandin C, et al. Malnutrition and food intake in relation to quality of life in head and neck cancer patients. Head Neck 1998; 20:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 2004; 12:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian J, Chen JS. Nutritional status and quality of life of the gastric cancer patients in Changle County of China. World J Gastroenterol 2005; 11:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med 1991; 325:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu SW, Kim IH. Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol 2010; 16:3310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JY, Wie GA, Cho YA, et al. Development and validation of a nutrition screening tool for hospitalized cancer patients. Clin Nutr 2011; 30:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009; 33:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arends J, Bodoky G, Bozzetti F, et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006; 25:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer JD, Ash S, Davidson WL, et al. Evidence-based guidelines for the nutritional management of cancer cachexia and chronic kidney disease. Nutr Dietetics 2006; 63:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robien K, Levin R, Pritchett E, et al. American Dietetic Association: standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in oncology nutrition care. J Am Diet Assoc 2006; 106:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bischoff SC, Austin P, Boeykens K, et al. ESPEN guideline on home enteral nutrition. Clin Nutr 2020; 39:5.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆. ESMO Open 2021; 6:100092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alderman B, Allan L, Amano K, et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer. Support Care Cancer 2022; 30:2983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 2006; 28:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halfdanarson TR, Thordardottir E, West CP, Jatoi A. Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. J Support Oncol 2008; 6:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol 2011; 185:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kathiresan AS, Brookfield KF, Schuman SI, Lucci JA 3rd. Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients. Arch Gynecol Obstet 2011; 284:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garth AK, Newsome CM, Simmance N, Crowe TC. Nutritional status, nutrition practices and post-operative complications in patients with gastrointestinal cancer. J Hum Nutr Diet 2010; 23:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sungurtekin H, Sungurtekin U, Balci C, et al. The influence of nutritional status on complications after major intraabdominal surgery. J Am Coll Nutr 2004; 23:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan MF, Pisters PW, Posner M, et al. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994; 220:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Detsky AS, Baker JP, O'Rourke K, Goel V. Perioperative parenteral nutrition: a meta-analysis. Ann Intern Med 1987; 107:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RC, Hartemink RJ, Hollinshead JW, Gillett DJ. Fine bore jejunostomy feeding following major abdominal surgery: a controlled randomized clinical trial. Br J Surg 1985; 72:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller JM, Keller HW, Brenner U, et al. Indications and effects of preoperative parenteral nutrition. World J Surg 1986; 10:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller JM, Brenner U, Dienst C, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982; 1:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000; 24:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987; 43:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeluga DJ, Stuart RK, Brookmeyer R, et al. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res 1987; 47:3309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charuhas PM, Fosberg KL, Bruemmer B, et al. A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. JPEN J Parenter Enteral Nutr 1997; 21:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iestra JA, Fibbe WE, Zwinderman AH, et al. Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies. Bone Marrow Transplant 1999; 23:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klimberg VS, Souba WW, Dolson DJ, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990; 66:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchman AL. Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001; 74:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pironi L, Paganelli GM, Miglioli M, et al. Morphologic and cytoproliferative patterns of duodenal mucosa in two patients after long-term total parenteral nutrition: changes with oral refeeding and relation to intestinal resection. JPEN J Parenter Enteral Nutr 1994; 18:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr 1989; 13:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992; 116:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN J Parenter Enteral Nutr 1993; 17:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson PM, Ramsay NK, Shu XO, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998; 22:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr 1999; 23:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991; 20:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockstein B, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998; 16:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Machtay M, Unger LD, et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly JM, Hearne B, Dunaj J, et al. Nutritional rehabilitation in patients with advanced head and neck cancer receiving radiation therapy. Am J Surg 1984; 148:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardy S, Haas K, Vanston VJ, Angelo M. Prophylactic Feeding Tubes in Head and Neck Cancers #318. J Palliat Med 2016; 19:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas S, Baumstarck-Barrau K, Alfonsi M, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial. Radiother Oncol 2009; 93:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nugent B, Parker MJ, McIntyre IA. Nasogastric tube feeding and percutaneous endoscopic gastrostomy tube feeding in patients with head and neck cancer. J Hum Nutr Diet 2010; 23:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis SL, Brody R, Touger-Decker R, et al. Feeding tube use in patients with head and neck cancer. Head Neck 2014; 36:1789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AM, Li BQ, Lau DH, et al. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2010; 78:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silander E, Nyman J, Bove M, et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck 2012; 34:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams GF, Teo MT, Sen M, et al. Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy? Oral Oncol 2012; 48:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson R, Karam I, Wilson G, et al. Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful? Support Care Cancer 2013; 21:3433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer S, Newcomb M, Hessler J, Siddiqui F. Prophylactic versus reactive PEG tube placement in head and neck cancer. Otolaryngol Head Neck Surg 2014; 150:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers SN, Thomson R, O'Toole P, Lowe D. Patients experience with long-term percutaneous endoscopic gastrostomy feeding following primary surgery for oral and oropharyngeal cancer. Oral Oncol 2007; 43:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcy PY, Magné N, Bensadoun RJ, et al. Systematic percutaneous fluoroscopic gastrostomy for concomitant radiochemotherapy of advanced head and neck cancer: optimization of therapy. Support Care Cancer 2000; 8:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magné N, Marcy PY, Foa C, et al. Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients. Eur Arch Otorhinolaryngol 2001; 258:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mekhail TM, Adelstein DJ, Rybicki LA, et al. Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 2001; 91:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assenat E, Thezenas S, Flori N, et al. Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy. J Pain Symptom Manage 2011; 42:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer KT, Krause KB, Zuercher T, Stanga Z. Early percutaneous endoscopic gastrostomy insertion maintains nutritional state in patients with aerodigestive tract cancer. Nutr Cancer 2005; 52:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nugent B, Lewis S, O'Sullivan JM. Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database Syst Rev 2013; :CD007904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corry J, Poon W, McPhee N, et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol 2008; 52:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanklyn P, Cox N, Belfield P. Outcome in patients who require a gastrostomy after stroke. Age Ageing 1995; 24:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayel H, el-Ghoneimy E, el-Haddad S. Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. Nutrition 1992; 8:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng X, Yu K, Wang G, et al. Effects of Immunonutrition on Chemoradiotherapy Patients: A Systematic Review and Meta-Analysis. JPEN J Parenter Enteral Nutr 2020; 44:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweinfurth JM, Boger GN, Feustel PJ. Preoperative risk assessment for gastrostomy tube placement in head and neck cancer patients. Head Neck 2001; 23:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyderman CH, Kachman K, Molseed L, et al. Reduced postoperative infections with an immune-enhancing nutritional supplement. Laryngoscope 1999; 109:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blomberg-van der Flier BM, et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr 2001; 73:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riccardi D, Allen K. Nutritional Management of Patients With Esophageal and Esophagogastric Junction Cancer. Cancer Control 1999; 6:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larrea J, Vega S, Martínez T, et al. [The nutritional status and immunological situation of cancer patients]. Nutr Hosp 1992; 7:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han-Geurts IJ, Hop WC, Tran TC, Tilanus HW. Nutritional status as a risk factor in esophageal surgery. Dig Surg 2006; 23:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassam Z, Wong RK, Ringash J, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2008; 20:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly JM, Weintraub FN, Shou J, et al. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995; 221:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windsor A, Braga M, Martindale R, et al. Fit for surgery: an expert panel review on optmising patients prior to surgery, with a particular focus on nutrition. Surgeon 2004; 2:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 1999; 134:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockeld D, Tennvall J, Wagenius G, et al. A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol 2001; 40:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkinson AD, Lim J, Agrawal N, Menzies D. Laparoscopic feeding jejunostomy in esophagogastric cancer. Surg Endosc 2007; 21:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolis M, Alexander P, Trachiotis GD, et al. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. Ann Thorac Surg 2003; 76:1694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy PM, Modi P, Rahamim J, et al. An investigation into the current peri-operative nutritional management of oesophageal carcinoma patients in major carcinoma centres in England. Ann R Coll Surg Engl 2006; 88:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odelli C, Burgess D, Bateman L, et al. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 2005; 17:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzetti F, Cozzaglio L, Gavazzi C, et al. Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival. Tumori 1998; 84:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sikora SS, Ribeiro U, Kane JM 3rd, et al. Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr 1998; 22:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heslin MJ, Latkany L, Leung D, et al. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann Surg 1997; 226:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds JV, Kanwar S, Welsh FK, et al. 1997 Harry M. Vars Research Award. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? JPEN J Parenter Enteral Nutr 1997; 21:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie AH, Prach AT, Baxter JP, Pennington CR. A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients. Gut 2000; 46:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedley F, Bowling T, James M, et al. Randomized clinical trial of the effects of preoperative and postoperative oral nutritional supplements on clinical course and cost of care. Br J Surg 2004; 91:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takagi K, Yamamori H, Morishima Y, et al. Preoperative immunosuppression: its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy. Nutrition 2001; 17:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takagi K, Yamamori H, Toyoda Y, et al. Modulating effects of the feeding route on stress response and endotoxin translocation in severely stressed patients receiving thoracic esophagectomy. Nutrition 2000; 16:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower MR, Martin RC 2nd. Nutritional management during neoadjuvant therapy for esophageal cancer. J Surg Oncol 2009; 100:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly JM, Massar E, Giacco G, et al. Parenteral nutrition in esophageal cancer patients. Ann Surg 1982; 196:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellrichmann M, Sergeev P, Bethge J, et al. Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers. Endoscopy 2013; 45:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobberup R, Thoresen L, Falkmer UG, et al. Effects of current parenteral nutrition treatment on health-related quality of life, physical function, nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh SY, Jun HJ, Park SJ, et al. A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route. J Palliat Med 2014; 17:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obling SR, Wilson BV, Pfeiffer P, Kjeldsen J. Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial. Clin Nutr 2019; 38:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santarpia L, Alfonsi L, Pasanisi F, et al. Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition 2006; 22:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Good P, Richard R, Syrmis W, et al. Medically assisted nutrition for adult palliative care patients. Cochrane Database Syst Rev 2014; :CD006274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arends J, Zuercher G, Dossett A, et al. Non-surgical oncology - Guidelines on Parenteral Nutrition, Chapter 19. Ger Med Sci 2009; 7:Doc09.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzetti F, Arends J, Lundholm K, et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009; 28:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoda D, Jatoi A, Burnes J, et al. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer 2005; 103:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 2006; 103:176.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2830 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32432946" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of Cancer Cachexia: ASCO Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17311654" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11606512" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : AGA technical review on parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16473073" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Home parenteral nutrition: survival, cost, and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10838261" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nutritional support of the cancer patient: issues and dilemmas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10763643" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7424938" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9713300" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18455316" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11269477" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The influence of nutritional status on complications after operations for lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9357024" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22269999" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18342966" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10679649" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The predictive value of body protein for chemotherapy-induced toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6799193" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of nutritional status on responses to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9702542" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Malnutrition and food intake in relation to quality of life in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14997369" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cancer: disease and nutrition are key determinants of patients' quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15786531" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nutritional status and quality of life of the gastric cancer patients in Changle County of China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1906987" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Perioperative total parenteral nutrition in surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20614488" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813215" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Development and validation of a nutrition screening tool for hospitalized cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713551" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697500" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Evidence-based guidelines for the nutritional management of cancer cachexia and chronic kidney disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16812928" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : American Dietetic Association: standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in oncology nutrition care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31255350" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : ESPEN guideline on home enteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31255350" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : ESPEN guideline on home enteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34144781" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34665311" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22345712" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327975" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18551861" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21074802" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20803205" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20337847" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Nutritional status, nutrition practices and post-operative complications in patients with gastrointestinal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190047" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The influence of nutritional status on complications after major intraabdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7944656" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3111322" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Perioperative parenteral nutrition: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3926036" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Fine bore jejunostomy feeding following major abdominal surgery: a controlled randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3083601" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Indications and effects of preoperative parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6119492" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Preoperative parenteral feeding in patients with gastrointestinal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969324" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10638466" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3109088" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3107808" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9168368" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10338050" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2354410" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prophylactic glutamine protects the intestinal mucosa from radiation injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11451714" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7933443" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Morphologic and cytoproliferative patterns of duodenal mucosa in two patients after long-term total parenteral nutrition: changes with oral refeeding and relation to intestinal resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2515303" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1567096" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8289404" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9722068" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10338217" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1993621" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632446" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469365" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9708712" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6385745" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Nutritional rehabilitation in patients with advanced head and neck cancer receiving radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27898295" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prophylactic Feeding Tubes in Head and Neck Cancers #318.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524315" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20337841" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Nasogastric tube feeding and percutaneous endoscopic gastrostomy tube feeding in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24478227" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Feeding tube use in patients with head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231073" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21374756" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22209648" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23949840" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24381015" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prophylactic versus reactive PEG tube placement in head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997615" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Patients experience with long-term percutaneous endoscopic gastrostomy feeding following primary surgery for oral and oropharyngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10975691" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Systematic percutaneous fluoroscopic gastrostomy for concomitant radiochemotherapy of advanced head and neck cancer: optimization of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11307612" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335904" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21477980" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16091001" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Early percutaneous endoscopic gastrostomy insertion maintains nutritional state in patients with aerodigestive tract cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440820" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19032398" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8588542" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Outcome in patients who require a gastrostomy after stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1562782" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920748" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31709589" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effects of Immunonutrition on Chemoradiotherapy Patients: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11295811" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Preoperative risk assessment for gastrostomy tube placement in head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10369282" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Reduced postoperative infections with an immune-enhancing nutritional supplement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157331" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10758536" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Nutritional Management of Patients With Esophageal and Esophagogastric Junction Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623048" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : [The nutritional status and immunological situation of cancer patients].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16888387" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Nutritional status as a risk factor in esophageal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10235156" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18345545" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7726669" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15712570" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Fit for surgery: an expert panel review on optmising patients prior to surgery, with a particular focus on nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9927128" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11669327" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17122985" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Laparoscopic feeding jejunostomy in esophagogastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602314" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16834854" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : An investigation into the current peri-operative nutritional management of oesophageal carcinoma patients in major carcinoma centres in England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16372491" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080677" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9437649" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Role of nutrition support during induction chemoradiation therapy in esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9351723" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9252944" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : 1997 Harry M. Vars Research Award. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807893" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286958" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Randomized clinical trial of the effects of preoperative and postoperative oral nutritional supplements on clinical course and cost of care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11165881" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Preoperative immunosuppression: its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10793304" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Modulating effects of the feeding route on stress response and endotoxin translocation in severely stressed patients receiving thoracic esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19373870" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Nutritional management during neoadjuvant therapy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6807225" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Parenteral nutrition in esophageal cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23780843" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31150954" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Effects of current parenteral nutrition treatment on health-related quality of life, physical function, nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24984081" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305245" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Home parenteral nutrition increases fat free mass in patients with incurable gastrointestinal cancer. Results of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16413750" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24760679" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Medically assisted nutrition for adult palliative care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20049066" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Non-surgical oncology - Guidelines on Parenteral Nutrition, Chapter 19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19477052" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15641035" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564074" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
